Claire Mazumdar Sells 10,000 Shares of Bicara Therapeutics (NASDAQ:BCAX) Stock

Bicara Therapeutics Inc. (NASDAQ:BCAX) CEO Claire Mazumdar sold 10,000 shares of the company’s stock in a transaction dated Friday, July 10th. The shares were sold at an average price of $28.42, for a total value of $284,200.00. Following the sale, the chief executive officer owned 362,152 shares in the company, valued at approximately $10,292,359.84. This represents a 2.69% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Claire Mazumdar also recently made the following trade(s):

• On Monday, April 20th, Claire Mazumdar sold 15,000 shares of Bicara Therapeutics stock. The shares were sold at an average price of $23.61, for a total transaction of $354,150.00.

Bicara Therapeutics Trading Up 0.0%

Shares of NASDAQ:BCAX opened at $28.11 on Thursday. The company has a 50 day moving average of $23.74 and a 200 day moving average of $20.34. The stock has a market cap of $1.85 billion, a P/E ratio of -10.11 and a beta of -0.81. Bicara Therapeutics Inc. has a 12 month low of $9.57 and a 12 month high of $30.99.

Bicara Therapeutics (NASDAQ:BCAX) last posted its earnings results on Monday, May 11th. The company reported ($0.93) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.72) by ($0.21). On average, equities analysts forecast that Bicara Therapeutics Inc. will post -3.48 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Bicara Therapeutics

A number of large investors have recently added to or reduced their stakes in the company. Deutsche Bank AG boosted its stake in Bicara Therapeutics by 0.9% in the fourth quarter. Deutsche Bank AG now owns 128,626 shares of the company’s stock worth $2,165,000 after buying an additional 1,171 shares in the last quarter. Legal & General Group Plc raised its stake in shares of Bicara Therapeutics by 64.1% during the second quarter. Legal & General Group Plc now owns 3,156 shares of the company’s stock worth $29,000 after acquiring an additional 1,233 shares in the last quarter. Mariner LLC raised its stake in shares of Bicara Therapeutics by 3.0% during the fourth quarter. Mariner LLC now owns 64,562 shares of the company’s stock worth $1,087,000 after acquiring an additional 1,902 shares in the last quarter. Invesco Ltd. lifted its holdings in shares of Bicara Therapeutics by 13.2% in the 2nd quarter. Invesco Ltd. now owns 16,877 shares of the company’s stock worth $157,000 after acquiring an additional 1,962 shares during the last quarter. Finally, Quantinno Capital Management LP lifted its holdings in shares of Bicara Therapeutics by 16.1% in the 1st quarter. Quantinno Capital Management LP now owns 17,612 shares of the company’s stock worth $350,000 after acquiring an additional 2,447 shares during the last quarter.

Analyst Ratings Changes

Several equities research analysts recently issued reports on the company. Wells Fargo & Company lifted their price objective on Bicara Therapeutics from $11.00 to $16.00 and gave the company an “equal weight” rating in a research note on Tuesday, March 31st. HC Wainwright upped their target price on Bicara Therapeutics from $40.00 to $42.00 and gave the stock a “buy” rating in a research note on Tuesday, March 31st. Guggenheim assumed coverage on Bicara Therapeutics in a report on Monday, May 11th. They issued a “buy” rating and a $42.00 price target on the stock. The Goldman Sachs Group lifted their price target on Bicara Therapeutics from $16.00 to $18.00 and gave the company a “neutral” rating in a research report on Tuesday, May 12th. Finally, Morgan Stanley boosted their price objective on Bicara Therapeutics from $36.00 to $37.00 and gave the stock an “overweight” rating in a report on Tuesday, May 12th. One research analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, Bicara Therapeutics presently has an average rating of “Moderate Buy” and a consensus target price of $30.27.

Bicara Therapeutics Company Profile

Bicara Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing novel neurohormone-based therapies for psychiatric and neurological disorders. The company’s research focuses on harnessing endogenous signaling pathways in the brain, with the goal of offering new treatment options for conditions that remain inadequately addressed by existing medications. Bicara applies proprietary peptide engineering and intranasal delivery platforms to optimize central nervous system uptake and therapeutic effect.

The company’s lead candidates include PST-001, an intranasal vasopressin-1A receptor antagonist in development for postpartum depression, and PST-002, an oxytocin receptor modulator being investigated for social anxiety and autism spectrum disorder.